Search results for "spondylarthriti"

showing 3 items of 23 documents

Fibromyalgia and arthritides

2012

Fibromyalgia (FM) is a chronic pain syndrome that affects at least 2% of the adult population. It is characterised by widespread pain, fatigue, sleep alterations and distress, and emerging evidence suggests a central nervous system (CNS) malfunction that increases pain transmission and perception. FM is often associated with other diseases that act as confounding and aggravating factors, such as rheumatoid arthritis (RA), spondyloarthritides (SpA), osteoarthritis (OA) and thyroid disease. Mechanism-based FM management should consider both peripheral and central pain, including effects due to cerebral input and that come from the descending inhibitory pathways. Rheumatologists should be able…

medicine.medical_specialtylcsh:Internal medicineCentral nervous systemlcsh:MedicineOsteoarthritisSeverity of Illness IndexArthritis RheumatoidDiagnosis DifferentialRheumatologyQuality of lifeFibromyalgiaOsteoarthritisSpondylarthritismedicineHumanspainAggravating Factorlcsh:RC31-1245FatiguePain Measurementbusiness.industryArthritisThyroid diseaselcsh:Rmedicine.diseaseThyroid DiseasesArthritides pain fibromyalgia rheumatic diseasesarthritidesDistressmedicine.anatomical_structurearthritides; fibromyalgia; pain; rheumatic diseasesRheumatoid arthritisPhysical therapyrheumatic diseasesfibromyalgiaChronic Painbusiness
researchProduct

Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease

2018

Objectives Vedolizumab (VDZ) blocks α4β7 integrin and is licenced for the treatment of IBD. It has been associated with mild SpA-related features, including sacroiliitis and synovitis. Herein we report a series of cases demonstrating the emergence of severe SpA-associated enthesitis/osteitis following successful IBD therapy with VDZ. Methods We evaluated 11 VDZ-treated patients with IBD across seven centres who developed severe active SpA and/or enthesopathy, with the aim of characterizing the VDZ-associated SpA or entheseal flares. Imaging features demonstrating particularly severe disease were recorded. Results De novo SpA developed in 9 of 11 patients and flare of known SpA in 2 patients…

musculoskeletal diseasesvedolizumabmedicine.medical_specialtySpondyloarthropathyenthesitimucosal vascular addressin cell adhesion molecule-1 (MADCAM-1)Vedolizumabulcerative coliti03 medical and health sciences0302 clinical medicineRheumatologyInternal medicinemedicinePharmacology (medical)030212 general & internal medicinespondyloarthritiα4β7 integrin030203 arthritis & rheumatologyCrohn's diseaseAnkylosing spondylitisbusiness.industryEnthesopathySacroiliitisEnthesitismedicine.diseaseankylosing spondylitispondylarthritiCrohn’Osteitismedicine.symptombusinessaxial SpAmedicine.drug
researchProduct

Metabolomics: An Emerging Approach to Understand Pathogenesis and to Assess Diagnosis and Response to Treatment in Spondyloarthritis

2022

Spondyloarthritis (SpA) is a group of rheumatic diseases whose pathogenesis relies on a complex interplay between genetic and environmental factors. Over the last several years, the importance of the alteration of the gut microbiota, known as dysbiosis, and the interaction of bacterial products with host immunity have been highlighted as intriguing key players in SpA development. The recent advent of the so called “-omics” sciences, that include metabolomics, opened the way to a new approach to SpA through a deeper characterisation of the pathogenetic mechanisms behind the disease. In addition, metabolomics can reveal potential new biomarkers to diagnose and monitor SpA patients. The aim of…

psoriatic arthritisQH301-705.5MicrobiotaPsoriatic arthritibiomarkersMetabolomicBiomarkerGeneral MedicineGastrointestinal MicrobiomeAnkylosing spondylitistomatognathic diseasesankylosing spondylitisSpondyloarthritisSpondylarthritisDysbiosisHumansMetabolomicsSpondylitis AnkylosingBiology (General)Cells
researchProduct